Blog

Diarrhea & Dehydration in Dairy & Beef Calves: Prevention

October 10, 2017

By Andre Teixeira, DVM, PhD, Veterinary Affairs Director, Jaguar Health Part 2 in a 3-part series on diarrhea and dehydration in dairy & beef calves Calf diarrhea is multifactorial in nature,…

Read More

Climate, Biodiversity & Indigenous Peoples

October 9, 2017

By Steven King, PhD, EVP, Sustainable Supply, Ethnobotanical Research & IP Indigenous Peoples Day is celebrated on the second Monday of October, and it is a day that is becoming…

Read More

Second Lease on Life for Shelter Dogs

October 3, 2017

By Stephen Palmer, Clinical Trial Manager According to the American Society for the Prevention of Cruelty to Animals (ASPCA), every year approximately 3.3 million doges enter animal shelters in the…

Read More

Diarrhea & Dehydration in Dairy & Beef Calves: General Overview

October 3, 2017

By Andre Teixeira, DVM, PhD, Veterinary Affairs Director, Jaguar Health Part 1 in a 3-part series on diarrhea and dehydration in dairy & beef calves Diarrhea, or scours, is a common…

Read More

The Goal: Zero by 30

September 27, 2017

By Peter Hodge, Director of Investor Relations & Market Research September 28th is World Rabies Day, a worldwide health observance started in 2007 by the Global Alliance for Rabies Control…

Read More

*Indication
MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information